ArticleNPJ Parkinson's disease2025
Associations of digestive diseases exposure and lifestyle factors with Parkinson's disease.
Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Chemically Programmed Prodrug Nanoparticles for Precise Oral Dopamine Delivery to Deep Brain Regions in Parkinson's Disease.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Long-Term Risk of Parkinson's Disease Following Irritable Bowel Syndrome: A Nationwide Population-Based Cohort Study.Healthcare (Basel, Switzerland) · 2026Article
- Cognitive reserve, frailty status, and risk of neurodegenerative diseases: a prospective cohort study.NPJ Parkinson's disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Emerging evidence highlights the importance of gastrointestinal (GI) dysfunction in Parkinson's disease (PD). While inflammatory bowel disease (IBD) has been linked to PD, the association with other GI conditions remains unclear. This study analyzed data from 501,483 participants, including 907 PD cases. Cox models revealed that digestive diseases were significantly associated with an increased PD risk (HR = 1.43). Eleven digestive diseases were linked to PD, with lifestyle factors such as sleep patterns and diet reducing PD risk. Notably, interactions between Non-alcoholic Fatty Liver Disease (NAFLD) and sleep (P-int = 0.0119), and Crohn's disease and dietary diversity (P-int = 0.0081) were observed. Population attributable fraction (PAF) analysis indicated that eliminating exposure to gastroesophageal reflux disease (GERD), gastritis and duodenitis, and gallbladder and biliary diseases could reduce PD cases by approximately 8.9%, 7.9%, and 3.8%, respectively. These findings emphasize the role of digestive diseases and lifestyle in PD risk.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.